Search Medical Condition
Please enter condition
Please choose location
 

North Potomac, Maryland Clinical Trials

A listing of North Potomac, Maryland clinical trials actively recruiting patient volunteers.

RESULTS

Found (1153) clinical trials

Treatment of Leishmaniasis With Impavido (Miltefosine): Pregnancy Registry

Objective: The purpose of this observational study is to fulfill FDA Post Marketing Requirement (PMR) 2127-1 for miltefosine (NDA204684): implement a pregnancy registry for the time period Mar 2015-Mar 2024. Study Design: This study is a prospective observational study in which female patients undergoing Impavido who become pregnant during treatment ...

Phase N/A

0.0 miles

Learn More »

Treatment of Leishmaniasis With Impavido (Miltefosine): Higher-Weight Patient Registry

Objective: The purpose of this observational study is to fulfill PMR 2127-4 for the miltefosine NDA (204684): implement a higher-weight-patient registry for the time period Mar 2015-Mar 2020. Study Design: This study is a prospective observational study in which patients undergoing treatment for leishmaniasis with Impavido in the US and ...

Phase N/A

0.0 miles

Learn More »

A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps

The purpose of this study is to determine the efficacy and safety of omalizumab compared with placebo in adult participants with chronic rhinosinusitis with nasal polyps (CRSwNP) who have had an inadequate response to standard-of-care treatments.

Phase

1.36 miles

Learn More »

RRx-001 in Small Non-small Cell Lung Cancer Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

This is an open label, four-arm, three stage, pilot study for co-administration of RRx-001 with autologous blood once weekly until progression followed by reintroduction of platinum-based doublet therapy. The study is designed to explore the potential of the epigenetic agent RRx-001 to sensitize patients who previously responded and now have ...

Phase

3.51 miles

Learn More »

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.

This is a phase 3 double-blind, randomized, placebo-controlled, study to assess the efficacy and safety of AZD9291 versus placebo in patients with stage IB-IIIA non-small cell lung cancer (NSCLC) with centrally confirmed, most common sensitising EGFR mutations (Ex19Del and L858R) either alone or in combination with other EGFR mutations as ...

Phase

3.51 miles

Learn More »

A Phase I Open-Label Multiple Ascending Dose Study of RRx-001 and Nivolumab

This is an open-label dose escalation study, consisting of the following periods: - 1) Screening Period (Up to 16 days): Eligibility for the study will be determined by Screening tests, physical examination/medical history, and fulfillment of eligibility criteria. Potential participants are required to provide written informed consent prior to the ...

Phase

3.51 miles

Learn More »

Electrical Stimulation for the Treatment of Post-Amputation Pain Using the SPRINT System

The purpose of this study is to determine if electrical stimulation (small levels of electricity) can safely and effectively reduce post-amputation pain. This study involves a device called the SPRINT System. The SPRINT System delivers mild electrical stimulation to nerves in the residual limb. The SPRINT System includes a small ...

Phase

3.51 miles

Learn More »

A Phase 2 Randomized Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer

Purpose This two-stage study is designed to compare the safety and activity between RRx-001 against regorafenib followed by irinotecan-based therapies in a parallel comparative study. Patients who are suffering from advanced or metastatic (meaning the disease has spread) colorectal cancer are invited to participate in this study. There will be ...

Phase

3.51 miles

Learn More »

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors that have progressed on standard of care therapy will be treated with pembrolizumab.

Phase

3.51 miles

Learn More »

Emricasan a Caspase Inhibitor for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis

This is a multicenter, double-blind, randomized, placebo-controlled trial involving subjects with a diagnosis of "definite NASH" with fibrosis (excluding cirrhosis) as determined by the central histopathologist. Upon successful screening, subjects will be randomized to receive either emricasan 50 mg BID or emricasan 5 mg BID or matching placebo BID.

Phase

3.51 miles

Learn More »